Neurocrine Biosciences is once again a top-rated biotech stock, despite recent setbacks for its depression and seizure treatments.
On Nov. 9, Neurocrine said a treatment for central beginning seizures neglected to show a significant decrease in seizure recurrence. Further, a downturn treatment neglected to meet the objective of a proof-of-idea study. Neurocrine tried it in individuals with anhedonia, the powerlessness to feel joy.
However, the second from last quarter report showed some potential gain for Neurocrine. Absolute deals popped practically 29% to $499 million, above assumptions for $479.1 million. Changed profit likewise came in at $1.54 per share, beating gauges by 20 pennies an offer and climbing 43%.